Kyverna Therapeutics Inc (KYTX) Stock Price, Quote & News

Company Profile

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; a...

Industry: Biotechnology

Sector: Healthcare

Phone: 510 925 2492

Website: kyvernatx.com

Address:

5980 Horton Street, Suite 550, Emeryville, United States

GetRollz Jan. 14 at 10:52 PM

$KYTX anyone actually see the presentation?

1 · Reply

GetRollz Jan. 14 at 10:50 PM

$KYTX

0 · Reply

BioRich Jan. 14 at 6:21 PM

$KYTX Amazing call. Truly exciting times for this company. This is just the beginning. Looking to ramp up commercialization, pipeline progress and pipeline growth and expansion. Significant cash position through 2028. Loaded a ton as soon as this call started and been smiling since. Follow/Subscribe for more suggestions and perspective from our growing community. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!

2 · Reply

BioRich Jan. 14 at 6:06 PM

$XBI $KYTX speaking now at JPM. Seem them as a huge BO candidate. Large cash position, strong pipeline (and expansion planned). Cheap here. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!

1 · Reply

NowTheFuture Jan. 14 at 5:59 PM

$KYTX Gilead already bought Kite after approval, this bird will be next too since using the same Car-T therapy.

0 · Reply

Madmortigan Jan. 14 at 5:41 PM

$KYTX damn can we at least hold some of these gains?!?!

1 · Reply

GTMStox Jan. 14 at 3:52 PM

$KYTX Why the P&D?

1 · Reply

BiodegradableBurger Jan. 14 at 3:43 PM

$KYTX We just got pumped and dumped.

0 · Reply

EingeLTrade Jan. 14 at 3:32 PM

⚕️ Kyverna Therapeutics Inc. $KYTX

0 · Reply

Th3M4skedSt0nker Jan. 14 at 3:21 PM

$KYTX big institutional buyers will start accumulating from today onwards 💲💲💲

0 · Reply

Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference

Jan 5, 2026, 8:00 AM EST - 9 days ago

Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference

Dec 18, 2025, 2:48 PM EST - 27 days ago

Kyverna Therapeutics: Taking The Next Step In Autoimmune Cell Therapies

Dec 17, 2025, 11:59 AM EST - 4 weeks ago

Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data From KYSA-8 Trial of Miv-cel in Stiff Person Syndrome Transcript

Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock

Dec 17, 2025, 9:24 AM EST - 4 weeks ago

Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome

Dec 14, 2025, 2:30 PM EST - 4 weeks ago

Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome

Stock Picks From Seeking Alpha's November 2025 New Analysts

Dec 8, 2025, 9:00 AM EST - 5 weeks ago

Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025

Oct 25, 2025, 11:00 AM EDT - 2 months ago

Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025

Oct 22, 2025, 8:00 AM EDT - 3 months ago

Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis

Sep 24, 2025, 9:05 AM EDT - 4 months ago

Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS

Sep 15, 2025, 1:02 PM EDT - 4 months ago

Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025

Aug 28, 2025, 8:00 AM EDT - 4 months ago

Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event

Kyverna Therapeutics to Present at Upcoming Investor Conferences in September

Aug 25, 2025, 4:02 PM EDT - 5 months ago

Investors in Kyverna Therapeutics, Inc. Should Contact The Gross Law Firm Before February 7, 2025 to Discuss Your Rights – KYTX

Feb 5, 2025, 11:54 AM EST - 1 year ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics

GetRollz Jan. 14 at 10:52 PM

$KYTX anyone actually see the presentation?

1 · Reply

GetRollz Jan. 14 at 10:50 PM

$KYTX

0 · Reply

BioRich Jan. 14 at 6:21 PM

2 · Reply

BioRich Jan. 14 at 6:06 PM

1 · Reply

NowTheFuture Jan. 14 at 5:59 PM

$KYTX Gilead already bought Kite after approval, this bird will be next too since using the same Car-T therapy.

0 · Reply

Madmortigan Jan. 14 at 5:41 PM

$KYTX damn can we at least hold some of these gains?!?!

1 · Reply

GTMStox Jan. 14 at 3:52 PM

$KYTX Why the P&D?

1 · Reply

BiodegradableBurger Jan. 14 at 3:43 PM

$KYTX We just got pumped and dumped.

0 · Reply

EingeLTrade Jan. 14 at 3:32 PM

⚕️ Kyverna Therapeutics Inc. $KYTX

0 · Reply

Th3M4skedSt0nker Jan. 14 at 3:21 PM

$KYTX big institutional buyers will start accumulating from today onwards 💲💲💲

0 · Reply

Th3M4skedSt0nker Jan. 14 at 3:19 PM

$KYTX congrats to everyone who bought on the post offering dip. Now back to double digit land. 💲💲💲

0 · Reply

Madmortigan Jan. 14 at 3:18 PM

$KYTX sell andbuy back in after drop?

0 · Reply

Rachel20201 Jan. 14 at 3:16 PM

$KYTX woooooow

0 · Reply

Jonita Jan. 14 at 3:12 PM

$KYTX ininin💣💣💣

0 · Reply

BiodegradableBurger Jan. 14 at 3:06 PM

$KYTX Ok did we get mentioned in some discord chat room?

1 · Reply

GetRollz Jan. 13 at 3:29 PM

$KYTX

0 · Reply

GetRollz Jan. 13 at 3:28 PM

$KYTX

0 · Reply

GetRollz Jan. 13 at 3:28 PM

$KYTX

0 · Reply

GetRollz Jan. 13 at 3:27 PM

$KYTX

0 · Reply

GetRollz Jan. 13 at 3:26 PM

$KYTX

0 · Reply

GetRollz Jan. 13 at 3:20 PM

$KYTX

0 · Reply

GetRollz Jan. 13 at 3:18 PM

$KYTX

0 · Reply

Market Cap	379.27M
Revenue (ttm)	0.00
Net Income (ttm)	-127.48M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,411,800
Avg Vol	1,601,752
Day's Range	N/A - N/A
Shares Out	43.80M
Stochastic %K	69%
Beta	3.45
Analysts	Strong Sell
Price Target	$28.20

Kyverna Therapeutics Inc (KYTX)

Company Profile

Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference

Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference

Kyverna Therapeutics: Taking The Next Step In Autoimmune Cell Therapies

Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data From KYSA-8 Trial of Miv-cel in Stiff Person Syndrome Transcript

Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock

Kyverna Therapeutics: "Strong Buy" Rating As Positive SPS Data Leads To 1st Half 2026 BLA Filing

Lightwave Logic, Kyverna Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Kyverna Therapeutics Announces Proposed Public Offering of Common Stock

Kyverna Therapeutics: Miv-Cel Delivers Breakthrough Data In Stiff Person Syndrome

Kyverna's cell therapy meets main goal of mid-stage study

Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome

Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome

Stock Picks From Seeking Alpha's November 2025 New Analysts

Kyverna Therapeutics: Immune Reset Is Clinically Validated, Market Ignores Potential

Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference

Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance

Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025

Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025

Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis

Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS

Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025

Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event

Kyverna Therapeutics to Present at Upcoming Investor Conferences in September

Kyverna Sets Pace In Race For Autoimmune CAR-T Approval By 2026

Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Kyverna Therapeutics to Host Virtual KOL Event to Highlight Neuroimmunology CAR T Franchise

Kyverna Therapeutics to Present at the Jefferies Global Healthcare Conference

With Trials In Motion, Cash To 2027, Can Kyverna's Next Data Drop Turn The Stock Around?

Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Kyverna: 2 Myasthenia Gravis Program Catalysts On Deck In 2025

Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference

KYTX Deadline: KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit

Investors in Kyverna Therapeutics, Inc. Should Contact The Gross Law Firm Before February 7, 2025 to Discuss Your Rights – KYTX

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics